Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how its connected technology can enhance anticounterfeiting and how data are handled within the product.
News|Articles|November 23, 2020
Samsung Biologics Signs MOU with Sartorius to Enhance Supply Chain for Biomedicines
Author(s)Pharmaceutical Technology Editors
The agreement follows a recent announcement that Sartorius plans to invest $100 million in Songdo, South Korea’s bio cluster.
Advertisement
Samsung Biologics has signed a memorandum of understanding (MOU) with Sartorius to further strengthen the supply chain for biomedicines. The MOU follows a recent announcement by Sartorius that the company plans to invest $100 million in South Korea's bio cluster, Songdo, to build a bioprocess manufacturing facility for equipment and materials, Samsung Biologics announced in a Nov. 16, 2020 press release.
Sartorius plans to supply materials such as disposable bags, cell culture media, and filters to Samsung Biologics. The facility will be built on a 24,333-m2 site in Songdo. Construction is expected to be completed by 2022.
Source:
Advertisement
Related to this article
Celtic Renewables won the CPHI Award for Sustainable Pharma Excellence for its green chemicals used in pharmaceutical manufacturing. Bettina Brierley, chief commercial officer, talks about the adoption, capacity, and pricing of biosolvents.
Terry Katz, CEO and cofounder of ForgeStop Technology Corporation, explains the company’s CPHI Award-winning connected product technology and how it helps to combat drug counterfeiting.
Bettina Brierley, chief commercial officer at Celtic Renewables, discusses commercialization of biosolvents for pharmaceutical manufacturing.
France’s 2030 Health Initiative is driving growth in biotechnology, health innovation, biomanufacturing, and digital health.
Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
argenx will acquire Unnatural Products for up to $1.15B, bringing oral macrocyclic peptides and new formulation challenges to its antibody portfolio.
CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing
Onshoring pharmaceutical manufacturing can be made more practical by collaborating with CDMOs that have gray space, supported by strong relationships with used equipment dealers and OEMs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
2
The Impact of Excipients on Continuous Manufacturing and the Risk of Nitrites
3
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
4
Drapeau’s AI Deep Dive: Qualify the Reviewer Before the AI Goes Live
5